On December 20, the Ministry of Health of the Russian Federation granted Generium permission to conduct phase II-III clinical trials of GNR-099, an intranasal vaccine against coronavirus infection.
According to the state register of permits for clinical trials, the nasal coronavirus vaccine will undergo trials in eight cities. These are Moscow, St. Petersburg, Saratov, Nizhny Novgorod, Saransk, Yaroslavl, Smolensk, and Voronezh.
The goal of the trial is stated as “to study the safety and immunogenicity of the intranasal GNR-099 vaccine in comparison with the Gam-COVID-Vac vaccine in healthy volunteers”.
The double randomized study of the safety and immunogenicity of the drug will involve 1,320 volunteers. It is to be compared with the indicators of Gum-Covid-Vac. The tests should be completed on December 31, 2023.
The fact that Generium developed a nasal form of the Sputnik V vaccine became known in October 2021.